Verrica Pharmaceuticals Inc Forecast, price target & analysts
Verrica Pharmaceuticals Inc Target price 2026 - Analyst rating & recommendation
Verrica Pharmaceuticals Inc Classifications & Recommendation
Verrica Pharmaceuticals Inc Price Target
| Target Price | $13.26 |
| Price | $4.37 |
| Potential |
203.43%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Verrica Pharmaceuticals Inc 2027 .
The average Verrica Pharmaceuticals Inc target price is $13.26.
This is
203.43%
register free of charge
$21.00
380.55%
register free of charge
$10.10
131.12%
register free of charge
|
|
| A rating was issued by 13 analysts: 11 Analysts recommend Verrica Pharmaceuticals Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Verrica Pharmaceuticals Inc stock has an average upside potential 2027 of
203.43%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 35.58 | 25.69 |
| 370.01% | 27.79% | |
| EBITDA Margin | -32.18% | -97.66% |
| 96.25% | 203.47% | |
| Net Margin | -50.28% | -114.58% |
| 95.03% | 127.88% |
9 Analysts have issued a sales forecast Verrica Pharmaceuticals Inc 2026 . The average Verrica Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Verrica Pharmaceuticals Inc EBITDA forecast 2026. The average Verrica Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2025 | $-11.5m | 82.35% |
|---|---|---|
| 2026 |
$-25.1m
119.14%
unlock
|
|
EBITDA Margin
| 2025 | -32.18% | 96.25% |
|---|---|---|
| 2026 |
-97.66%
203.47%
unlock
|
|
8 Verrica Pharmaceuticals Inc Analysts have issued a net profit forecast 2026. The average Verrica Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.68 | -1.71 |
| 88.63% | 1.79% | |
| P/E | negative | |
| EV/Sales | 2.60 |
8 Analysts have issued a Verrica Pharmaceuticals Inc forecast for earnings per share. The average Verrica Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
Verrica Pharmaceuticals Inc...
Current Verrica Pharmaceuticals Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Brookline Capital |
Locked
➜
Locked
|
Locked | Dec 18 2025 |
| Needham |
Locked
➜
Locked
|
Locked | May 14 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Apr 09 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Dec 20 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 06 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Brookline Capital:
Locked
➜
Locked
|
Dec 18 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Apr 09 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 08 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Dec 20 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 06 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
